A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

NACompletedINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Indinavir sulfate

DRUG

Lamivudine

DRUG

Zidovudine

Trial Locations (1)

Merck & Co Inc, Whitehouse Station

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY